Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss

Circulation

Volumn 113, Issue 2, 2006, Pages 273-279

  Mehilli, Julinda ^a   Kastrati, Adnan ^a   Wessely, Rainer ^a   Dibra, Alban ^a   Hausleiter, Jörg ^a   Jaschke, Birgit ^a   Dirschinger, Josef ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coronary disease; Drugs; Restenosis; Stents

Indexed keywords

PACLITAXEL; POLYMER; RAPAMYCIN; BIOMATERIAL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG ELUTING STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; THROMBOGENICITY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; GRAFT OCCLUSION; MIDDLE AGED; STANDARD; STENT; SURVIVAL RATE;

AGED; COATED MATERIALS, BIOCOMPATIBLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; POLYMERS; SIROLIMUS; STENTS; SURVIVAL RATE;

EID: 33644784297     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.575977     Document Type: Article

References (26)

1. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents, part I. Circulation. 2003;107:2274-2279.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
4. Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005;45:1206-1212.
5. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521.
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi G, Airoldi F, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
7. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106:2649-2651.
8. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705.
9. Rogers CD. Drug-eluting stents: clinical perspectives on drug and design differences. Rev Cardiovasc Med. 2005;6:S3-S12.
10. Leon M. Microporous and nanoporous non-polymeric stent surfaces for drug elution. Available at: http://www.tctmd.com/csportal/appmanager/ tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=800746. Accessed June 7, 2005.
11. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, Behnisch B, Schratzenstaller T, Renke-Gluszko M, Stover M, Wintermantel E, Kastrati A, Schömig A. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005;25:748-753.
12. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schömig A. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005;26:1475-1481.
13. Dibra A, Kastrati A, Mehilli J, Pache J, von Oepen R, Dirschinger J, Schömig A. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. Cathet Cardiovasc Interv. 2005;65:374-380.
14. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection: Multivessel Angioplasty Prognosis Study Group. Circulation. 1990;82:1193-1202.
15. O'Brien RG, Muller KE. Applied Analysis of Variance in Behavioural Science. New York, NY: Marcel Dekker; 1993.
16. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York, NY: Marcel Dekker; 1992.
17. Teirstein PS. Living the dream of no restenosis. Circulation. 2001;104:1996-1998.
18. Wessely R, Kastrati A, Schömig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005;143:392-394.
19. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697.
20. Virmani R. Complications of percutaneous coronary intervention - pathology. ESC Congress 2004, Munich, Germany. Available at: http://www.escardio.org/knowledge/OnlineLearning/slides/ ESC_Congress_2004_Munich/RVirmaniFP239/. Accessed June 7, 2005.
21. Palmaz JC, Benson A, Sprague EA. Influence of surface topography on endothelialization of intravascular metallic material. J Vasc Interv Radiol. 1999;10:439-444.
22. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhofer D, Schühlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schömig A. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004;110:790-795.
23. Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428-1436.
24. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schömig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol. 1999;83:1617-1622.
25. Mauri L, O'Malley AJ, Popma JJ, Moses JW, Leon MB, Holmes DR Jr, Teirstein PS, Cutlip DE, Donahoe D, Kuntz RE. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005;95:1140-1145.
26. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215-1223.